secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-107339
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics Q2 2025 net loss $7.4M; cash $29.8M; ENLIGHTEN 2 Phase 3 met primary endpoint
--------------------------------------------------------------------------------

- Net loss Q2 2025 $7.4M vs $48.1M YoY due to lower R&D and no impairment charges.
- Cash $29.8M at June 30, 2025; $5.0M gross financing extends runway into Q3 2026.
- ENLIGHTEN 2 Phase 3 met primary endpoint: 3CS improvement -1.13 (p=0.0078) at week 24; key secondary endpoints also met.
- Preparing for Type C meeting with FDA in H2 2025 to align on NDA submission path for LYR-210 in CRS without nasal polyps.
- Completed 1-for-50 reverse stock split in May; regained Nasdaq minimum bid compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000095017025107339/0000950170-25-107339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000095017025107339/lyra-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer